Cisplatin-ineligible patients with metastatic urothelial carcinoma treated with PD-1/L1 inhibitor followed by carboplatin-containing chemotherapy show similar overall survival (OS) with those treated with the reverse sequence, a study has found.
Use of vibegron in addition to α-1 blocker or phosphodiesterase 5 (PDE5) inhibitor is safe and effective in the treatment of patients with benign prostatic hyperplasia (BPH) and persistent storage symptoms, as shown in a study.
Oral sodium bicarbonate with Lactated Ringer’s solution (LR) is a good option for urine alkalization to ease nephrotoxicity caused by high-dose methotrexate (MTX; doses ≥500 mg/m2), suggests a study. Moreover, the total dose of sodium bicarbonate used is lower in the oral than the intravenous (IV) cohort, with no additional delays in clearance.
Oestradiol, raloxifene, and the proprietary phytoestrogen compound rimostil appear to convey no therapeutic benefits in perimenopause-related depression (PMD), as shown in a study. However, oestradiol has the potential to improve depression ratings than rimostil.
Use of a single-agent temozolomide appears to be an effective alternative to late adjuvant therapy in patients with melanoma if novel treatments, such as targeting and immune therapies, are not available, suggests a recent study.
The glucagon-like peptide-1 receptor agonist semaglutide appears safe and effective in the treatment of patients with nonalcoholic steatohepatitis (NASH), resulting in a higher rate of resolution than placebo, according to the results of a phase II trial. There is, however, little effect on fibrosis stage.
Use of the computerized insulin dosing tool (CIDT) with 24-hour pharmacist monitoring is efficacious and safe for the treatment of diabetic ketoacidosis (DKA) as compared with a provider-driven insulin dosing strategy, suggests a study.
The combination of ivermectin 1% cream (IVM) and doxycycline 40-mg modified-release capsules (DMR) delivers faster responses, better response rates and greater satisfaction compared with monotherapy in patients with severe rosacea, a recent study has shown.
New drug applications approved by US FDA as of 16 - 31 May 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.